

CV Date	16/05/2022
----------------	------------

Part A. PERSONAL INFORMATION

First Name *	Antonio		
Family Name *	Llombart Cussac		
Sex *	Male	Date of Birth *	03/11/1964
ID number Social Security, Passport *	19850939F	Phone Number *	(+34) 963513435
URL Web			
Email Address	allombart1@yahoo.com		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0003-4515-8293	
	Researcher ID		
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Head of the Oncology Department		
Starting date	2011		
Institution	Arnau de Vilanova Hospital		
Department / Centre			
Country		Phone Number	
Keywords	Medicine		

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor in Medicine	Universitat de València / Spain	2007

A.4. General quality indicators of scientific production

Publications: 229 articles in international journals (Publons), 3 books and 12 book chapters. Head of Medical oncology Hospital Arnau Vilanova and associated professor Universidad Católica Valencia.

More than 70 indexed publications in the last 5 year. For reasons of space, only those of the last two years are mentioned.

Several books and book chapter as well as more than 250 congress oral and poster presentation.

IndexH: 42. Citations: 7513

9 Competitive funding projects. 2021 PI for ISCIII grant on TNBC and 2 grants on Cancer, Covid and microbiota from European Recovery funds.

Scientific expert in several scientific committees. Board member of SEOM, ESMO, ASCO, AACR.

Past Scientific director (2006-2009) and president (2009 - 2014) of the SOLTI group. He has also been actively involved in the GEICAM Spanish group for Breast Cancer. Academic member of the Real Academia Medicina de la Comunidad Valenciana

2005: SOLTI AWARD

Cofounder and Breast Cancer senior advisor for MedSIR a private company focusing on clinical research trials. International PI for 12 currently ongoing clinical trials within the MedSIR program

Expert consultant for Eli Lilly, Novartis, Pfizer, Roche, AstraZeneca, Agendia, ExactSciences, MSD, Seagen, Pierre Fabre as well as the French Institut National du Cancer (INCA)

Intellectual property: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY (2019) ID:16/467,019

Fellowships and Mobility

Social Security Research Fund and European TATIANA. Institut Gustave Roussy, France

Young investigators in cancer. Lilly company. Indianapolis, US

SEOM. Memorial Sloan Kettering Cancer Center, New York

Novartis research fellow

-Doctoral thesis supervision: 4 thesis completed (Cum Laude qualification). Currently directing 4 doctoral theses (University of Valencia)

-Master's thesis supervision: 3 completed

-Supervision of Final Degree Projects: 4 (Catholic University of Valencia and University of Valencia)

Part B. CV SUMMARY

MD, PhD is Head of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain and founding partner of Medica Scientia Innovation Research (MedSIR). In 2007, He obtained his PhD in Medicine at the Valencia University.

He received his medical training in Pamplona and Valencia, finalizing a Medical Oncology degree from the University Hospital in Valencia. After his fellowship period (1994 to 1997) in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and II studies), He became a medical staff member for two years in this french institution. Upon his return to Valencia, He chaired the Breast Cancer Research Unit at the Instituto Valenciano de Oncología and, later, at the Medical Oncology Service of the University Hospital Arnau de Vilanova in Lleida, Spain, with a multidisciplinary scientific clinical unit made up of pharmacologists, surgeons, pathologists and biologists working with cytotoxic and molecular agents both in human and animal models. His main current focus is on translational clinical trials and correlative science in the neoadjuvant management of breast cancer patients.

He is an active member of the Spanish and European clinical oncology community, working together with many international cooperative groups (BIG, GEICAM, SOLTI) and designing innovative clinical trials. He is also a Board Member of the Spanish Society of Medical Oncology.

Antonio is also an expert consultant for several pharmaceutical companies (Eli Lilly, Novartis, Pfizer Oncology and Boehringer Ingelheim, Pierre Fabre) as well as the Institut National du Cancer (INCA), Paris, France. His contributions, as a member of the International Scientific Committee, in several pivotal international studies in breast cancer (P024, ZO-FAST) have helped to develop new drugs and, also, new therapeutical strategies. Antonio is Academic member of the Real Academia Medicina de la Comunidad Valenciana

Antonio's research interest is focused on biology, origin, new biomarkers and characterization molecular of breast cancer. For this, he combines clinical studies and biochemical, molecular and cellular functional assays. As PI, he has directed 4 doctoral theses, three Master's theses and has mentored 4 undergraduate students for periods of 2-6 months. He has financed his research with international, national, public and private grants from Carlos III institution and different pharmaceuticals.

He is a member of Editorial Board of the journal Oncologie, La revue francophone de formation en Oncologie and author of more than 291 peer-reviewed publications and he has more than 250 congress oral and poster presentation.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Gion M; Pérez-García JM; Llombart Cussac A; Sampayo M; Cortes J; Malfettone A. (3/6). 2021. Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects *Ther Adv Med Oncol.* 13:17588359211059587.
- 2 **Scientific paper.** Prat A; Guarneri V; Pascual T; et al; Llombart Cussac A; Perou CM. (13/27). 2022. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer *EBioMedicine.* 75-103801.
- 3 **Scientific paper.** Toi M; Neven P; Sohn J; et al; Llombart-Cussac A; Sledge GW. (5/10). 2022. Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant *Clin Cancer Res.* 14-28 (8), pp.1500-1506.
- 4 **Scientific paper.** Llombart-Cussac A; Cortés J; Perez-Garcia J. (3/3). 2021. CDK4/6 inhibitors in breast cancer: spotting the difference *Nature Medicine.* 27-11, pp.1868-1869.
- 5 **Scientific paper.** Griguolo G; Serna G; Pascual T; et al; Llombart Cussac A; Nuciforo P. (12/25). 2021. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. *NPJ Precis Oncol.* 19-5, pp.23.
- 6 **Scientific paper.** Inoue K; Masuda N; Iwata H; et al; Llombart- Cussac A; Toi M.(14/16). 2021. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor- positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy *Breast Cancer.*
- 7 **Scientific paper.** Andreu JC; Pons A; González A; Lombart-Cussac A; Cano MJ; Cuellar C. (4/6). 2021. Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality. *PLoS One.* 13-16, pp.e0256205.
- 8 **Scientific paper.** Neven N; Johnston SRD; Toi M,; et al; Llombart-Cussac A; Sledge GW. (17/18). 2021. MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR⁺, HER2⁻-Advanced Breast Cancer *Clin Cancer Res.* 27-215801, pp.5801-5809.
- 9 **Scientific paper.** Pascual T; Oliveira M; Villagrasa P; et al; Llombart-Cussac A; Cortés J. (15/20). 2021. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial *NPJ Breast Cancer.* 25-7, pp.145.
- 10 **Scientific paper.** 2021. PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication *Ann. Oncol.* 32-10, pp.1245-1255.
- 11 **Scientific paper.** Pérez-García JM; Gebbart G; Ruiz Borrego A; et al; J, Llombart-Cussac A (AC). (22/22). 2021. PHERGain steering committee and trial investigators. Chemotherapy de-escalation using an ¹⁸F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non- comparative, phase 2 trial. *Lancet Oncol.* 22-6, pp.858-871.
- 12 **Scientific paper.** Gris-Oliver A; Ibrahim YH; Rivas MA; et al; Llombart Cussac A; Serra V. (9/24). 2021. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer *Br. J. Cancer.* 124-9, pp.1581-1591.
- 13 **Scientific paper.** Pérez Gracia JM; Llombart Cussac A; Cortés M; et al; Cortes J. (2/19). 2021. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open- label, multicentre, single-arm, phase II trial. *Eur. J. Cancer.* 148, pp.382-394.
- 14 **Scientific paper.** Sampayo Cordero; Miguel-Huguet B; Malfettone A; Perez GarcíaJM; Llombart-Cussac A; Pérez López J. (5/6). 2021. The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: "The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis *Front Mol Biosci.* 8, pp.690615.

- 15 **Scientific paper.** Prat A; Guarneri V; Paré L; et al; Llombart-Cussac A; Conte P. (26/39). 2020. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncol.* 21-11, pp.1455-1464.
- 16 **Scientific paper.** Romero I; Rubio MJ; Medina M; et al; Llombart Cussac A; Poveda A. (15/16). 2020. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study *Gynecol Oncol.* 159-3, pp.721-731.
- 17 **Scientific paper.** Jacobs SA; Robidoux A; Abraham J; et al; Llombart-Cussac A; Pogue-Geile KL. (12/26). 2020. Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. *Breast cancer research : BCR.* 22, pp.9. ISSN 1465-5411. <https://doi.org/10.1186/s13058-019-1240-y>
- 18 **Scientific paper.** Andreu JC; Galindo L; Hidalgo J; et al; Llombart Cussac A (AC). (11/11). 2020. Differences in circulating $\gamma\delta$ T cells in patients with primary colon cancer and relation with prognostic factors. *PlosOne.* 16-15, pp.e0243545..
- 19 **Scientific paper.** Jacobs S.; Robidoux A.; Abraham J.; et al; Llombart-Cussac A.; Pogue-Geile K.(12/26). 2020. Erratum: Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast cancer research : BCR (2019) 21 1 (133)) *Breast cancer research : BCR.* 22, pp.9. <https://doi.org/10.1186/s13058-019-1240-y>
- 20 **Scientific paper.** Prat A.; Pascual T.; De Angelis C.; et al; Llombart-Cussac A.; Rimawi M.(5/35). 2020. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade *Journal of the National Cancer Institute.* 112, pp.46-54. SCOPUS (6) <https://doi.org/10.1093/jnci/djz042>
- 21 **Scientific paper.** Garde J; Fernández-Murga ML; Giner V; et al; Llombart Cussac A. (10/10). 2020. Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population *Cancers (Basel).* 25-12, pp.3513.
- 22 **Scientific paper.** Sampayo M; Miguel Huguet B; Pérez Garcia J; et al; Llombart Cussac A; Cortés J. (12/13). 2020. Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design. *Contemp Clin Trials Commun.* 28-20, pp.100678.
- 23 **Scientific paper.** Schettini F; Giudici F; Giuliano M; et al; Llombart-Cussac A; Generali D. (15/20). 2020. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta- Analysis. *J Natl Cancer Inst.* 112-11, pp.1089-1097.
- 24 **Scientific paper.** Manso L; Hernando C; Galan M; et al; Llombart Cussac A; Moreno F. (10/35). 2020. Palbociclib combined with endocrine therapy in heavily pretreated HR⁺/HER2⁻ advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). *Breast.* 54, pp.286-292.
- 25 **Scientific paper.** Brasó-Maristany F.; Griguolo G.; Pascual T.; et al; Llombart-Cussac A.; Prat A.(6/28). 2020. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade *Nature Communications.* 11. <https://doi.org/10.1038/s41467-019-14111-3>
- 26 **Scientific paper.** Santiago-O'Farrill J.; Weroha S.; Hou X.; et al; Llombart-Cussac A.; Bast R.(15/18). 2020. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models *Cancer.* 126, pp.894-907. ISSN 0008543X. <https://doi.org/10.1002/cncr.32600>
- 27 **Scientific paper.** Prat, Aleix; Saura, Cristina; Pascual, Tomas; et al; Llombart-Cussac, Antonio; Gavila, Joaquin. (18/30). 2020. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial *LANCET ONCOLOGY.* 21. ISSN 1470-2045. WOS (1) [https://doi.org/10.1016/S1470-2045\(19\)30786-7](https://doi.org/10.1016/S1470-2045(19)30786-7)

- 28 **Scientific paper.** Lope V; Guerrero A; Casas A; et al; Llombart Cussac A; Pollán M. (17/23). 2020. Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. *Nutrients*. 14-12, pp.3132.
- 29 **Scientific paper.** Sledge G.; Toi M.; Neven P.; et al; Llombart-Cussac A. (AC). (19/19). 2020. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy - MONARCH 2: A Randomized Clinical Trial *JAMA Oncology*. 6, pp.116-124. ISSN 23742437. SCOPUS (8) <https://doi.org/10.1001/jamaoncol.2019.4782>
- 30 **Scientific paper.** López Miranda E; Pérez Garcia JM; Di Cosimo S; et al; Llombart Cussac A; Cortes J. (13/15). 2020. Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial *Cancers (Basel)*. 25-12, pp.3509.
- 31 **Scientific paper.** Griguolo, G.; Holgado, E.; Cortes, J.; et al; LLombart-Cussac, A. (AC). (21/21). 2019. Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy *CANCER RESEARCH*. 79. ISSN 0008-5472. <https://doi.org/10.1158/1538-7445.SABCS18-P6-17-08>
- 32 **Scientific paper.** Braso-Maristany, F.; Griguolo, G.; Llombart-Cussac, A.; et al; Prat, A.(3/21). 2019. Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer *CANCER RESEARCH*. 79. ISSN 0008-5472. <https://doi.org/10.1158/1538-7445.SABCS18-P6-17-07>
- 33 **Scientific paper.** Sledge, G. W.; Toi, M.; Neven, P.; et al; Llombart-Cussac, A. (AC). (19/19). 2019. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer *ANNALS OF ONCOLOGY*. 30. ISSN 0923-7534. WOS (1)
- 34 **Scientific paper.** Llombart Cussac, Antonio (AC); Perez-Garcia, Jose; Guerrero, Angel; et al; Cortes, Javier. (1/22). 2019. Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score (R) (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial) *CANCER RESEARCH*. 79. ISSN 0008-5472. <https://doi.org/10.1158/1538-7445.AM2019-CT219>
- 35 **Scientific book or monograph.** Mañfettone A; Di Cosimo S; Perez-Gracia JM; et al; Llombart Cussac A; Cortés J. (8/10). 2021. Nobody dares stopping clinical research, not even COVID-19. *NPJ Breast Cancer*. 8-7, pp.39.
- 36 **Review.** Gil-Gil M; Alba E; Gavilá J; de la Haba-Rodriguez J; Ciruelos E; Tolosa P; Candini D. (8/8). 2021. The role of CDK4/6 inhibitors in early breast cancer. *Breast*. 25-58, pp.160-169.
- 37 **Scientific-technical report.** Llombart-Cussac A (AC); Perez Garcia J; et. al. (1/16). 2021. PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial *JAMA Oncol*.7-12, pp.1791-1799.

C.3. Research projects and contracts

- 1 **Project.** Células T CD8+ agotadas y mieloides supresoras (MDSC) en cáncer triple negativo metastásico: La ruta Notch, un nuevo jugador en pacientes tratadas con inhibidores del punto de control inmunitario.. Instituto de Salud Carlos III. Antonio Llombart. (Instituto de Salud Carlos III). 2021-2024. 183.900 €. Principal investigator.
- 2 **Project.** Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study. 2018-2023. Co-ordinator.
- 3 **Project.** International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in hormone receptor-positive/HER2-negative Advanced Breast Cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment.. 2018-2023. Co-ordinator.
- 4 **Project.** Efficacy and immune response of mRNA vaccines to SARS-CoV-2 in cancer patients under active treatment. Antonio Llombart Cussac. (Fondos de Recuperación Europeo-FISABIO). 2021-2022. 76.000 €.

- 5 **Project.** Influence of the intestinal microbiome on COVID-19 infection and the effectiveness of immunotherapy in cancer patients –BICOIN. Y.Sanz. (Consejo Superior de Investigaciones Científicas). 2020-2022. 120.000 €. Team member.
- 6 **Project.** Neoadjuvancy with Letrozole and Palbociclib in patients with stage II-IIIb breast cancer, RH (+) / HER2 (-) phenotype and Recurrence Score (Oncotype-Dx) Intermediate (18-25) or High (> 25) with analysis of changes in the RS to surgery.. 2018-2021. Co-ordinator.
- 7 **Project.** A randomized, multicentre, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic breast cáncer. 2018-2020. Co-ordinator.
- 8 **Project.** Observational, retrospective and multicenter study to evaluate the clinical benefit of the combination of trastuzumab and lapatinib (tl) in patients with HER2 positive metastatic breast cancer and previously treated with trastuzumab and / or lapatinib. 2014-2019. Co-ordinator.
- 9 **Project.** Breast cancer: Prognostic utility of Protein Expression Profiles in patients with viable residual tumor (> 1.0 cm) after neoadjuvant chemotherapy.. A Llombart Cussac. (Instituto de Salud Carlos III). 2009-2012. 96.000 €. Team member.
- 10 **Project.** Cancer Genomics. (Instituto de Salud Carlos III). From 2013. Team member.
- 11 **Project.** A new biomarker in the differential diagnosis of malignancy / benignity in patients with pleural effusion: extracellular histones in pleural fluid. (Impulsa Bancaja-Fisabio). From 2012. Co-ordinator.
- 12 **Contract.** MK-7339-009 An Opel-label, Randomized, Phase 2-3 Study of Olaparib Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab Alter Induction of Clinical Bedit with firts-line Chemotherapy Plus Pembrolizumab in Paticipants with Locally Recurrent, Inoperable or Metastasic Triple Negative Breast Cancer A Llombart. From 2020.
- 13 **Contract.** Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[-] PIK3ca-mutated advanced breast cancer patients treated with alpelisib plus endocrine therapy. the metallica study 2020-01/01/2021.
- 14 **Contract.** Aromatase Inhibitors for Luminal-like (HER2-negative, ER-positive) and gBRCA or HRD-positive Metastatic Breast Cancer. 2019-01/01/2020.
- 15 **Contract.** DEXCARTES (MedOpp199) Neoadjuvant Letrozole and palbociclib in patients with Stage II-IIIB Breast Cancer, HR[+] HER2[-], phenotype and pre-treatment recurrence score (RS) result 18-25 or 26-100 by Oncotype Dx Breast RS Assay.Analysis of RS an pathological changes at surgery V.Carañana. From 2019.
- 16 **Contract.** MK-3475-173 A phase 1B Study to Evaluate afety and Clinical Activity of Pembrolizumab (MK 3475) in combination with Chemotherapy as Neoadjuvant Treatment for the Tiple Negative Breast Cancer From 2019.
- 17 **Contract.** MK-3475-756 A Ranomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in combination with Neoadjuvant chemotherapy and Adjuvant Endocrine therapy for the treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth factor Receptor 2 Negative (ER+/HER2-) Breast Cancer From 2019.
- 18 **Contract.** NOBROLA (MedOpp100) A two-stage Simon Design Phase II study for Non-BRCA metastasic BReast Cancer (MBC) patients with homologous recombination deficiency treated with OLaparib single agent. V.Carañana. From 2019.
- 19 **Contract.** OPHELIA (MedOp 168) Effectiveness of Olaparib plus Trastuzumab in HER2-positive BRCA- mutated or Homologous. Recombination Deficiency (HRD) advanced breast cancer patient V.Carañana. From 2019.
- 20 **Contract.** PACIFIC-6 (D4194C00006) A phase II, open-label, multi-centre, international safety study of Durvalumab following sequential chemotherapy and radiation therapy in patients with stage III, unresectable non-small cell lung cancer. A.LLombart. From 2019.
- 21 **Contract.** PALMIRA (MedOpp 068) Internacional, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second line endocrine therapy in hormone receptor positive / HER2 negative Advanced Breast Cancer patients who have archived clinical benefit during first-line palbociclib based treatment A. Llombart. From 2019.

- 22 Contract.** Phase 2 clinical trial to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer. 2019-01/01/2020.
- 23 Contract.** of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain clinical study 2019-01/01/2021.
- 24 Contract.** 18- HER 2 CLIMB Phase 2 Randomized- Double- Blinded, Controlled Study of tucatinib vs Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable locally Advanced or metastatic HER2+ Breast Carcinoma (ONT-380-206 A. Llombart. From 2018.
- 25 Contract.** CLEEOIIA2404 An Open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/post menopausal women with hormone receptor positive (HR+), HER2-negative (HER2-) advanced breast Cancer (ABC) with no prior hormonal therapy for advanced disease. A Llombart. From 2017.
- 26 Contract.** PARSIFAL A Randomized, multicentre, open-label, phase II trial to evaluate the efficacy and Safety of palbociclib in Combination with Fulvestran or letrozole in patients with HER2 negative ER+ metastatic breast cancer A Llombart. From 2017.

C.4. Activities of technology / knowledge transfer and results exploitation

Antonio Llombart-Cussac; Aleix Prat Aparicio; Javier Cortes. HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY United States of America. 05/06/2019.